Autologous hematopoietic stem cell transplantation did not improve outcomes for patients with mantle cell lymphoma and undetectable minimal residual disease.

Key Market Players Profiled include Illumina, Qiagen, PerkinElmer, F. Hoffmann-La Roche, Thermo Fisher Scientific, Natera, Bio-Rad Laboratories, Adaptive Biotechnologies, Sysmex, Integrated DNA ...

At the American Society of Hematology annual meeting, a roundtable discussion highlighted the evolving role of minimal residual disease (MRD) as a treatment endpoint in multiple myeloma, exploring its ...

Panelists discuss how minimal residual disease assessment demonstrates superior depth of response with ciltacabtagene autoleucel compared with standard of care in patients who have ...

Researchers sought to determine if HRQoL measures differ with gilteritinib compared with placebo in patients with AML.

Edgardo S. Santos, MD, FACP, FASCO, highlighted how liquid biopsies are transforming lung cancer care by enabling faster, ...

Practice-changing studies in both frontline CLL and relapsed/refractory disease, presented at ASH 2024, are discussed by Dr Jennifer Woyach.

Adaptive Biotechnologies’ management is scheduled to present on Tuesday, January 14th at 5:15 p.m. Pacific Time / 8:15 p.m. Eastern Time. Interested parties may access a live and archived webcast of ...

Dr John Leonard shares key updates on DLBCL at ASH 2024, including long-term POLARIX trial data, ctDNA insights, and real-world results for polatuzumab, liso-cel, and bispecifics after CAR-T failure.